Galapagos' selective JAK1 inhibitor filgotinib meets key efficacy endpoints, shows ACR70 responses up to 39%, and maintains safety profile after 24 weeks of treatment in DARWIN 1 Phase 2B study
Didn't make notes yet but a Couple Comments from first listen: 1-Abbvie has 60 days from Darwin 2 ("any day") results to decide on licensing. Would "gladly" wave criteria requiring them to listen if they are not interested. 2-1 Death happened because of Pneumonia not clear if drug related as happened in hospital outside of investigator. 3 Weeks prior blood work was normal (nothing to show concern). 3-Not concerned with high dose in male patients. Monitored male hormone and no safety signal also in Darwin 3 much more males on high dose also did preclinical studies that think give freedom to operate.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.